Apimeds Pharmaceuticals Us's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Apimeds Pharmaceuticals Us's ROA in the second quarter of 2026?
Apimeds Pharmaceuticals Us, Inc. recorded a cumulative net loss of $-50 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -45.29%.

However, within the Healthcare sector Apimeds Pharmaceuticals US, Inc. achieved the highest return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3787, from total ROA ranking in the first quarter of 2026 at 3862.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	1108.53 %	54235.98 %	13332.36 %	656.77 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-50	-33	-6	-5	-4
Return On Assets (TTM)	-45.29 %	-40.03 %	-13.03 %	-96.95 %	-111.95 %
APUS's Total Ranking	# 3787	# 3862	#	#	#
Total Assets (TTM) in million	127	141	164	9	11
Seq. Total Assets Change	-9.74 %	-13.99 %	1674.96 %	-12.29 %	3957.98 %
Seq. Net Income Change	-	-	-	-	-

APUS's 5 Years Annual ROA >> Back to APUS Management Effectiveness >> Compare APUS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	# 0

Return On Assets Statistics
High	Average	Low
-13.03 %	-32.78 %	-45.27 %
(Dec 31 2025)		(Jun 30 2026)

Financial Statements
Apimeds Pharmaceuticals Us's Assets	$ 127 million	APUS's Balance sheet
Apimeds Pharmaceuticals Us's Income	$ -20 million	Quarterly APUS's Income Statement
APUS's Income by Division		See APUS's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2023) FY 2024	FY	FY	FY
Y / Y Total Assets Change	1400.81 %	-	-	-	-
Total Assets in million	18	1	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-6	-1	0	0	0
Annual Return On Assets	-32.71 %	-63.63 %	-	-	-

APUS's 5 Years Annual ROA >> Back to APUS Management Effectiveness >> Compare APUS ROA to its Competitors

More Return On Assets Ratios
APUS's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
APUS's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for APUS's Competitors
Subscribers only: Roa for Apimeds Pharmaceuticals Us's Suppliers
Subscribers only: Return On Assets for APUS's Customers

You may also want to know
APUS's Roi	APUS's Inventory Turnover Ratio	APUS's Growth Rates	APUS's Dividend Comparisons
	APUS's Profitability Ratios	APUS's Asset Turnover Ratio	APUS's Dividend Growth
APUS's Roe	APUS's Valuation Ratios	APUS's Financial Strength Ratios	APUS's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-12T06:29:04+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.